Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV ...

The Food and Drug Administration has launched a safety review of two approved RSV drugs for infants, the latest immunizations ...

There's hope for U.S. cattle ranchers in the battle to stop the spread of screwworm at a time of decimated herds with the FDA ...

One catalyst happened a couple of weeks ago, when Merck's stock popped by nearly 4% on encouraging clinical data. Let's look ...

Patients with polycythemia vera (PV), a rare cancer characterized by overabundant red blood cells, have endured years of middling progress in their therapeutic options. | Patients with polycythemia ...

This degree of success can become a double-edged sword, though. While the drug has thrived since its first approval back in 2014, its patent protection will begin expiring in 2028. This will allow ...

In today's Pharmalittle roundup, we're reading about FDA's Prasad defending his plans, a Merck setback in Germany, and more.

Merck’s investigational antibody MK-2214 has received fast-track designation from the FDA for the treatment of Alzheimer’s disease. MK-2214 targets phosphorylated serine 413 tau (pS413), a marker of ...

In two studies, semaglutide failed to slow decline in thousands of people with early stages of Alzheimer's disease.

Smaller studies and animal research had hinted it could help with brain inflammation or slow cognitive decline, but larger trials were needed to prove it.

Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the makers of Wegovy and Mounjaro are seeking FDA approval for tablets.